Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
CONCLUSION: The findings from this study suggest that 12 weeks' treatment of sofosbuvir plus daclatasvir and sofosbuvir plus ledipasvir was both efficacious and well tolerated treatment in Egyptian patients with HCV genotype 4 infection.
PMID: 31573893 [PubMed - as supplied by publisher]
Source: Current Drug Safety - Category: Drugs & Pharmacology Authors: Abdelaty LN, Elnaggar AA, Said AA, Hussein RRS Tags: Curr Drug Saf Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Drugs & Pharmacology | Egypt Health | Headache | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Laboratory Medicine | Liver | Liver Cancer | Migraine | Study | Urology & Nephrology | Virology